This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Nagasaka M , Asad MFB , Al Hallak MN , Uddin MH , Sukari A , Baca Y , Xiu J , Magee D , Mamdani H , Uprety D , Kim C , Xia B , Liu SV , Nieva JJ , Lopes G , Bepler G , Borghaei H , Demeure MJ , Raez LE , Ma PC , Puri S , Korn WM , Azmi AS
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
Lung Cancer. 2021 Oct;160 :92-98
AbstractBACKGROUND: Nuclear protein transport is essential in guiding the traffic of important proteins and RNAs between the nucleus and cytoplasm. Export of proteins from the nucleus is mostly regulated by Exportin 1 (XPO1). In cancer, XPO1 is almost universally hyperactive and can promote the export of important tumor suppressors to the cytoplasm. Currently, there are no studies evaluating XPO1 amplifications and mutations in NSCLC and the impact on outcomes. METHODS: Tumor samples were analyzed using next-generation sequencing (NGS) (NextSeq, 592 Genes), immunohistochemistry (IHC), and whole transcriptome sequencing (WTS, NovaSeq) (Caris Life Sciences, Phoenix, AZ). Survival was extracted from insurance claims data and calculated from time of tissue collection to last contact using Kaplan-Meier estimate. RESULTS: Among 18,218 NSCLC tumors sequenced, 26 harbored XPO1 mutations and 24 had amplifications. XPO1 mutant tumors were more likely to have high TMB (79% vs. 52%, p = 0.007) and less likely to have high PD-L1 (32% vs. 68%, p = 0.03). KRAS co-mutations were seen in 19% (n = 5) and EGFR co-mutations were rare (n = 2). Among the 17,449 NSCLC tumors with clinical data, there were 24 XPO1 mutant. Comparison of survival between XPO1 mutant and WT showed a negative association with a hazard ratio (HR) of 1.932 (95% CI: 1.144-3.264 p = 0.012). XPO1 amplification was not associated with survival. CONCLUSIONS: XPO1 pathogenic mutations were associated with a poor survival in NSCLC. Although XPO1 mutations are rare in NSCLC, further studies to assess its associations with treatment responses are warranted.
Notes1872-8332 Nagasaka, Misako Asad, Mohammad Fahad B Al Hallak, Mohammed Najeeb Uddin, Md Hafiz Sukari, Ammar Baca, Yasmine Xiu, Joanne Magee, Dan Mamdani, Hirva Uprety, Dipesh Kim, Chul Xia, Bing Liu, Stephen V Nieva, Jorge J Lopes, Gilberto Bepler, Gerold Borghaei, Hossein Demeure, Michael J Raez, Luis E Ma, Patrick C Puri, Sonam Korn, W Michael Azmi, Asfar S Journal Article Ireland Lung Cancer. 2021 Oct;160:92-98. doi: 10.1016/j.lungcan.2021.08.010. Epub 2021 Aug 27.